恶性淋巴瘤临床转化研究进展

Translational research progress in malignant lymphoma

目前临床上广泛应用的利妥昔单抗联合化疗可明显改善多种B细胞淋巴瘤患者的预后，但仍有约1/3的晚期患者会由于多种原因导致初次治疗无效或短期有效但复发、进展。近年来恶性淋巴瘤相关临床转化研究日益受到重视，所开发出的靶向药物将进一步为患者临床治疗指明方向。文章就第58届美国血液学会年会在恶性淋巴瘤临床转化研究领域的最新成果进行总结。

Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma （B-NHL）, but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug. Recently, many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma. The advances in translational research field were summarized in this manuscript.